Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02541604 |
|---|---|
| Brief Title: | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors |
| First Submitted : | August 18, 2015 |
| First Submitted that Met QC Criteria : | September 3, 2015 |
| First Posted : | September 4, 2015 (Estimate) |
| Results First Submitted : | November 11, 2019 |
| Results First Submitted that Met QC Criteria : | February 24, 2020 |
| Results First Posted : | February 25, 2020 |
| Last Update Submitted that Met QC Criteria : | February 24, 2020 |
| Last Update Posted : | February 25, 2020 |